Tom 5, Nr 3-4 (2024)
Opis przypadku
Opublikowany online: 2025-01-20
Wyświetlenia strony
14
Wyświetlenia/pobrania artykułu
3
Rak płuca u chorych na idiopatyczne włóknienie płuc — opis serii przypadków
1, 2
DOI: 10.5603/pp.99751
Pneum Pol 2024;5(3-4):188-196.
Streszczenie
Idiopatyczne włóknienie płuc (IPF, idiopathic pulmonary fibrosis) jest przewlekłą i postępującą chorobą układu oddechowego,
charakteryzującą się rozlanym włóknieniem miąższu płuc o nieznanej etiologii, która prowadzi do rozwoju niewydolności oddychania
oraz przedwczesnego zgonu. IPF często współistnieje z innymi chorobami układu oddechowego, w tym z rakiem płuca (LC,
lung cancer). LC u chorych na IPF występuje częściej niż w populacji ogólnej i jest to związane z wspólną patogenezą na poziomie
molekularnym i epigenetycznym. Zachorowanie na LC znacznie pogarsza rokowanie chorych na IPF. Diagnostyka i leczenie LC u chorych
na IPF są utrudnione i wiążą się z wyższym ryzykiem powikłań, ale są możliwe i skuteczne. Niniejszy artykuł, stanowiący opis
trzech przypadków klinicznych, porusza problematykę procesu diagnostyczno-terapeutycznego LC u chorych na IPF.
Słowa kluczowe: idiopatyczne włóknienie płucrak płuca
Referencje
- Piotrowski WJ, Bestry I, Białas AJ, et al. Guidelines of the Polish Respiratory Society for diagnosis and treatment of idiopathic pulmonary fibrosis. Adv Respir Med. 2020; 88(1): 41–93.
- Piotrowski WJ, Martusewicz-Boros MM, Białas AJ, et al. Idiopathic pulmonary fibrosis (IPF) - common practice in Poland before the "antifibrotic drugs era". Adv Respir Med. 2017; 85(3): 136–142.
- Barratt SL, Creamer A, Hayton C, et al. Idiopathic Pulmonary Fibrosis (IPF): An Overview. J Clin Med. 2018; 7(8).
- Noble PW, Albera C, Bradford WZ, et al. CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011; 377(9779): 1760–1769.
- King TE, Bradford WZ, Castro-Bernardini S, et al. ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22): 2083–2092.
- Richeldi L, du Bois RM, Raghu G, et al. INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22): 2071–2082.
- Lederer DJ, Martinez FJ. Idiopathic Pulmonary Fibrosis. N Engl J Med. 2018; 378(19): 1811–1823.
- Sharif R. Overview of idiopathic pulmonary fibrosis (IPF) and evidence-based guidelines , vol. 23, no. 11 Suppl, pp. Am J Manag Care. 2017; 23(11): 176–182.
- Bade B, Cruz CD. Lung Cancer 2020. Clinics in Chest Medicine. 2020; 41(1): 1–24.
- Ballester B, Milara J, Cortijo J. Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets. Int J Mol Sci. 2019; 20(3).
- Ozawa Y, Suda T, Naito T, et al. Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology. 2009; 14(5): 723–728.
- Tomassetti S, Gurioli C, Ryu JH, et al. The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest. 2015; 147(1): 157–164.
- Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209–249.
- Cottin V, Selman M, Inoue Y, et al. Syndrome of Combined Pulmonary Fibrosis and Emphysema: An Official ATS/ERS/JRS/ALAT Research Statement. Am J Respir Crit Care Med. 2022; 206(4): e7–ee41.
- Kawasaki H, Ogura T, Yokose T, et al. p53 gene alteration in atypical epithelial lesions and carcinoma in patients with idiopathic pulmonary fibrosis. Hum Pathol. 2001; 32(10): 1043–1049.
- Samarelli AV, Masciale V, Aramini B, et al. Molecular Mechanisms and Cellular Contribution from Lung Fibrosis to Lung Cancer Development. Int J Mol Sci. 2021; 22(22).
- Kinoshita T, Goto T. Molecular Mechanisms of Pulmonary Fibrogenesis and Its Progression to Lung Cancer: A Review. Int J Mol Sci. 2019; 20(6).
- Takenaka K, Gemma A, Yoshimura A, et al. Reduced transcription of the Smad4 gene during pulmonary carcinogenesis in idiopathic pulmonary fibrosis. Mol Med Rep. 2009; 2(1): 73–80.
- Frank AJ, Dagogo-Jack I, Dobre IA, et al. Management of Lung Cancer in the Patient with Interstitial Lung Disease. Oncologist. 2023; 28(1): 12–22.
- Kato E, Takayanagi N, Takaku Y, et al. Incidence and predictive factors of lung cancer in patients with idiopathic pulmonary fibrosis. ERJ Open Res. 2018; 4(1).
- Hiwatari N, Shimura S, Takishima T, et al. Bronchoalveolar lavage as a possible cause of acute exacerbation in idiopathic pulmonary fibrosis patients. Tohoku J Exp Med. 1994; 174(4): 379–386.
- Sakamoto K, Taniguchi H, Kondoh Y, et al. Acute exacerbation of IPF following diagnostic bronchoalveolar lavage procedures. Respir Med. 2012; 106(3): 436–442.
- Dhooria S, Mehta RM, Srinivasan A, et al. The safety and efficacy of different methods for obtaining transbronchial lung cryobiopsy in diffuse lung diseases. Clin Respir J. 2018; 12(4): 1711–1720.
- Amundson WH, Racila E, Allen T, et al. Acute exacerbation of interstitial lung disease after procedures. Respir Med. 2019; 150: 30–37.
- Sato T, Teramukai S, Kondo H, et al. Japanese Association for Chest Surgery. Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. J Thorac Cardiovasc Surg. 2014; 147(5): 1604–1611.e3.
- Sato T, Watanabe A, Kondo H, et al. Japanese Association for Chest Surgery. Long-term results and predictors of survival after surgical resection of patients with lung cancer and interstitial lung diseases. J Thorac Cardiovasc Surg. 2015; 149(1): 64–9, 70.e1.
- Goto T. Measuring Surgery Outcomes of Lung Cancer Patients with Concomitant Pulmonary Fibrosis: A Review of the Literature. Cancers (Basel). 2018; 10(7).
- Kanaji N, Tadokoro A, Kita N, et al. Impact of idiopathic pulmonary fibrosis on advanced non-small cell lung cancer survival. J Cancer Res Clin Oncol. 2016; 142(8): 1855–1865.
- Nakao S, Yamaguchi K, Sakamoto S, et al. Chemotherapy-associated Acute Exacerbation of Interstitial Lung Disease Shortens Survival Especially in Small Cell Lung Cancer. Anticancer Res. 2019; 39(10): 5725–5731.
- Ozawa Y, Abe T, Omae M, et al. Impact of Preexisting Interstitial Lung Disease on Acute, Extensive Radiation Pneumonitis: Retrospective Analysis of Patients with Lung Cancer. PLoS One. 2015; 10(10): e0140437.
- Miura Y, Saito T, Tanaka T, et al. Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone. Respir Investig. 2018; 56(1): 72–79.
- Reck M, Kaiser R, Mellemgaard A, et al. LUME-Lung 1 Study Group. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014; 15(2): 143–155.
